Clinical Trial Update: Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the effect of twice-daily exenatide on glucose control and safety/tolerability in adults with Type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• EXENATIDE (EXENATIDE)

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED